Bicycle Therapeutics PLC (BCYC) stock prices were up by 5.47% shortly after market trading commenced on October 8th 2021. This brought the price per share up to USD$51.35 early on in the trading day.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
BTC Clinical Trials
October 7th 2021 saw BCYC announce a clinical update of its wholly owned, next generation Bicycle Toxin Conjugates (BTCs). The biotechnology company’s update included interim results from its Phase 1 trial of BT5528 and preliminary findings from its ongoing dose escalation portion of the BT8009 clinical trial. Both trials exhibited preliminary anti-tumor activity across two tumor types. The treatments also reported tolerability profiles that have the potential to demonstrate differentiation from antibody-based approaches. BYCY stock has a history of developing a novel class of medicines, referred to as Bicycles. These treatments are for diseases with a significant unmet need. They are fully synthetic short peptides constrained with small molecule scaffolds.
Scope of Positive Data
The data supports the company’s belief that BCYC stock’s platform offers a differentiated approach to traditional toxin delivery. The data generated from these molecules has provided invaluable information and insights for the company as it expands the application of its technology. The company is concurrently generating additional Bicycle-targeted therapeutics with the aim of making a meaningful difference for cancer patients. Additional clinical data on BT5528 and BT8009 are expected in 2022, with the initiation of Phase 1 and 2 studies for BT7480 are expected for later in the current year.
BCYC Stock’s BT5528
A total of 24 patients were dosed both before and after the execution of the EphA2 immunohistochemistry (IHC) assay. The dosing had a median of seven prior lines of therapy. Preliminary anti-tumor activity was observed in urothelial and ovarian cancer patients from the 24 patients. A total of 2 BT5528 monotherapy urothelial patients were administered with the treatment. Both patients exhibited tumor reductions, which amounts to a partial response under Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 the doses were administered once every 2 weeks and ranged from 6.5mg/m2 to 10mg/m2.
Future Outlook for BCYC Stock
The company reported a strong quarter, consolidated by the promising developments from its various ongoing studies. BCYC stock is poised to capitalize on the expanded scope of opportunities afforded to it as a result of the momentum it has generated. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal. This is hoped to facilitate consistent and organic increases in shareholder value over the long term.